CRC Research Update — September 03, 2026
Today's colorectal cancer research highlights
her2
A collection of 32 issues
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
Skip to content
The CRC Digest
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology)
This content is informational only and does not constitute
HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance
Skip to content
The CRC Digest
▸ TREATMENT
HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance
Narrative review outlines practical patient selection and treatment sequencing for HER2-targeted therapies in metastatic colorectal cancer, focusing on RAS wild-type disease with HER2 overexpression or ERBB2 amplification, including dual HER2
CRC Research Update — August 28, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 22, 2026
Today's colorectal cancer research highlights
HER2 amplification studied in resectable CRC
Skip to content
The CRC Digest
HER2 amplification studied in resectable CRC
A study of 3,607 patients with resectable colorectal cancer investigated the prognostic impact of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy efficacy and circulating tumor DNA. (Int J Clin Oncol)
This content is informational only
CRC Research Update — August 01, 2026
Today's colorectal cancer research highlights
HER2-mutated colorectal cancers show distinct genomic features from HER2-amplified tumors
Skip to content
The CRC Digest
◇ RESEARCH
HER2-mutated colorectal cancers show distinct genomic features from HER2-amplified tumors
Analysis of 4,348 CRC patients found that ERBB2/HER2 mutations occurred in 2.2% and amplifications in 2.0%, with distinct genomic landscapes and clinical characteristics between the two groups. (Oncologist)
This
Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC
A study found that liquid biopsy can guide rechallenge with anti-HER2 therapy in patients with HER2-amplified metastatic colorectal cancer. (JCO Precision Oncology)
This content is informational only and does not constitute medical advice.
Always
CRC Research Update — July 31, 2026
Today's colorectal cancer research highlights